Antiplatelet agents for the treatment and prevention of atherothrombosis

Carlo Patrono; Felicita Andreotti; H Arnesen; L Badimon; C Baigent; J Collet; R De Caterina; D Gulba; K Huber; S Husted; Sd Kristensen; J Morais; F Neumann; Lh Rasmussen; A Siegbahn; P Steg; Rf Storey; F Van De Werf; F. Verheugt

doi:10.1093/eurheartj/ehr373

Antiplatelet agents for the treatment and prevention of atherothrombosis

Carlo Patrono, Felicita Andreotti, H Arnesen, L Badimon, C Baigent, J Collet, R De Caterina, D Gulba, K Huber, S Husted, Sd Kristensen, J Morais, F Neumann, Lh Rasmussen, A Siegbahn, P Steg, Rf Storey, F Van De Werf, F. Verheugt

Risultato della ricerca: Contributo in rivista › Articolo in rivista

174 Citazioni (Scopus)

Abstract

The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.

Lingua originale	English
pagine (da-a)	2922-2932
Numero di pagine	11
Rivista	European Heart Journal
Volume	32
DOI	https://doi.org/10.1093/eurheartj/ehr373
Stato di pubblicazione	Pubblicato - 2011

Keywords

Coronary Artery Disease
Coronary Thrombosis
Drug Therapy, Combination
Humans
Platelet Activation
Platelet Aggregation Inhibitors
Risk Factors

Accesso al documento

10.1093/eurheartj/ehr373

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Patrono, C., Andreotti, F., Arnesen, H., Badimon, L., Baigent, C., Collet, J., De Caterina, R., Gulba, D., Huber, K., Husted, S., Kristensen, S., Morais, J., Neumann, F., Rasmussen, L., Siegbahn, A., Steg, P., Storey, R., Van De Werf, F., & Verheugt, F. (2011). Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal, 32, 2922-2932. https://doi.org/10.1093/eurheartj/ehr373

@article{835d3cc86df442628970d5c2622df4b6,

title = "Antiplatelet agents for the treatment and prevention of atherothrombosis",

abstract = "The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.",

keywords = "Coronary Artery Disease, Coronary Thrombosis, Drug Therapy, Combination, Humans, Platelet Activation, Platelet Aggregation Inhibitors, Risk Factors, Coronary Artery Disease, Coronary Thrombosis, Drug Therapy, Combination, Humans, Platelet Activation, Platelet Aggregation Inhibitors, Risk Factors",

author = "Carlo Patrono and Felicita Andreotti and H Arnesen and L Badimon and C Baigent and J Collet and {De Caterina}, R and D Gulba and K Huber and S Husted and Sd Kristensen and J Morais and F Neumann and Lh Rasmussen and A Siegbahn and P Steg and Rf Storey and {Van De Werf}, F and F. Verheugt",

year = "2011",

doi = "10.1093/eurheartj/ehr373",

language = "English",

volume = "32",

pages = "2922--2932",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford : Oxford University Press United Kingdom: Harcourt Publishers Limitedinternational.com, Fax: 011 44 20 83085876",

}

Patrono, C, Andreotti, F, Arnesen, H, Badimon, L, Baigent, C, Collet, J, De Caterina, R, Gulba, D, Huber, K, Husted, S, Kristensen, S, Morais, J, Neumann, F, Rasmussen, L, Siegbahn, A, Steg, P, Storey, R, Van De Werf, F & Verheugt, F 2011, 'Antiplatelet agents for the treatment and prevention of atherothrombosis', European Heart Journal, vol. 32, pagg. 2922-2932. https://doi.org/10.1093/eurheartj/ehr373

TY - JOUR

T1 - Antiplatelet agents for the treatment and prevention of atherothrombosis

AU - Patrono, Carlo

AU - Andreotti, Felicita

AU - Arnesen, H

AU - Badimon, L

AU - Baigent, C

AU - Collet, J

AU - De Caterina, R

AU - Gulba, D

AU - Huber, K

AU - Husted, S

AU - Kristensen, Sd

AU - Morais, J

AU - Neumann, F

AU - Rasmussen, Lh

AU - Siegbahn, A

AU - Steg, P

AU - Storey, Rf

AU - Van De Werf, F

AU - Verheugt, F.

PY - 2011

Y1 - 2011

N2 - The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.

AB - The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.

KW - Coronary Artery Disease

KW - Coronary Thrombosis

KW - Drug Therapy, Combination

KW - Humans

KW - Platelet Activation

KW - Platelet Aggregation Inhibitors

KW - Risk Factors

KW - Coronary Artery Disease

KW - Coronary Thrombosis

KW - Drug Therapy, Combination

KW - Humans

KW - Platelet Activation

KW - Platelet Aggregation Inhibitors

KW - Risk Factors

UR - http://hdl.handle.net/10807/8606

U2 - 10.1093/eurheartj/ehr373

DO - 10.1093/eurheartj/ehr373

M3 - Article

SN - 0195-668X

VL - 32

SP - 2922

EP - 2932

JO - European Heart Journal

JF - European Heart Journal

ER -

Antiplatelet agents for the treatment and prevention of atherothrombosis

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo